Advertisement

Journal of Thrombosis and Thrombolysis

, Volume 41, Issue 2, pp 234–240 | Cite as

Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation

  • Mark H. Eckman
Article

Abstract

Until recently, vitamin K antagonists, warfarin being the most commonly used agent in the United States, have been the only oral anticoagulant therapies available to prevent stroke in patients with atrial fibrillation (AF). In the last 5 years four new, non-vitamin K oral anticoagulants, the so-called NOACs or novel oral anticoagulants, have come to market and been approved by the Federal Drug Administration. Despite comparable if not superior efficacy in preventing AF-related stroke, and generally lower risks of major hemorrhage, particularly intracranial bleeding, the uptake of these agents has been slow. A number of barriers stand in the way of the more widespread use of these novel agents. Chief among them is concern about the lack of antidotes or reversal agents. Other concerns include the need for strict medication adherence, since missing even a single dose can lead to a non-anticoagulated state; out-of-pocket costs for patients; the lack of easily available laboratory tests to quantitatively assess the level of anticoagulant activity when these agents are being used; contraindications to use in patients with severe chronic kidney disease; and black-box warnings about the increased risk of thromboembolic events if these agents are discontinued prematurely. Fortunately, a number of reversal agents are in the pipeline. Three reversal agents, idarucizumab, andexanet alfa, and aripazine, have already progressed to human studies and show great promise as either antidotes for specific drugs or as universal reversal agents. The availability of these reversal agents will likely increase the clinical use of the non-vitamin K oral anticoagulants. In light of the many complex and nuanced issues surrounding the choice of an optimal anticoagulant for any AF patient, a patient-centered/shared decision-making approach will be useful.

Keywords

Anticoagulation Non-vitamin K oral anticoagulants Warfarin Atrial fibrillation Quality improvement 

References

  1. 1.
    Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 155:469–473PubMedGoogle Scholar
  2. 2.
    Wolf PA, Singer DE (1997) Preventing stroke in atrial fibrillation. Am Fam Physician 56:2242–2250PubMedGoogle Scholar
  3. 3.
    Wolf PA, Abbott RD, Kannel WB (1987) Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med. 147:1561–1564CrossRefPubMedGoogle Scholar
  4. 4.
    Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, Ilstrup DM, Frye RL (1987) The natural history of lone atrial fibrillation. A population-based study over three decades. The New England journal of medicine. 317:669–674CrossRefPubMedGoogle Scholar
  5. 5.
    Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001) Prevalence of Diagnosed Atrial Fibrillation in Adults: national Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 285:2370–2375CrossRefPubMedGoogle Scholar
  6. 6.
    Kaba RA, Ahmed O, Cannie D (2014) Response to ‘Lack of reversibility for NOACs’. Glob Cardiol Sci Pract 2014(1):2PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Al-Kindi S (2014) Lack of reversibility for NOACs. Glob Cardiol Sci Pract 2014(1):1PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Southworth MR, Reichman ME, Unger EF (2013) Dabigatran and postmarketing reports of bleeding. N Engl J Med 368:1272–1274CrossRefPubMedGoogle Scholar
  9. 9.
    Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC (2012) National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 5:615–621PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    AbuDagga A, Stephenson JJ, Fu AC, Kwong WJ, Tan H, Weintraub WS (2014) Characteristics affecting oral anticoagulant therapy choice among patients with non-valvular atrial fibrillation: a retrospective claims analysis. BMC Health Serv Res. 14:310PubMedCentralCrossRefPubMedGoogle Scholar
  11. 11.
    Huang C, Siu M, Vu L, Wong S, Shin J (2013) Factors influencing doctors’ selection of dabigatran in non-valvular atrial fibrillation. J Eval Clin Pract. 19:938–943PubMedGoogle Scholar
  12. 12.
    Schoof N, Schnee J, Schneider G, Gawlik M, Zint K, Clemens A, Bartels DB (2014) Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US. Curr Med Res Opin 30:795–804CrossRefPubMedGoogle Scholar
  13. 13.
    Steinberg BA, Holmes DN, Piccini JP, Ansell J, Chang P, Fonarow GC, Gersh B, Mahaffey KW, Kowey PR, Ezekowitz MD, Singer DE, Thomas L, Peterson ED, Hylek EM (2013) Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc. 2:e000535PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    NICE Implementation Collaborative (2014) NICE Implementation collaborative consensus—supporting local implementation of nice guidance on the use of the novel (non-vitamin K antagonist) oral anticoagulants in non-valvular atrial fibrillation. National Institute for Health and Care ExcellenceGoogle Scholar
  15. 15.
    Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, Wood P, McLintock C (2014) New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 44:525–536CrossRefPubMedGoogle Scholar
  16. 16.
    Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH (2012) Evidence-based management of anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e152S–e184SPubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM (2004) The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 164:880–884CrossRefPubMedGoogle Scholar
  18. 18.
    Dowlatshahi D, Butcher KS, Asdaghi N, Nahirniak S, Bernbaum ML, Giulivi A, Wasserman JK, Poon MC, Coutts SB (2012) Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke 43:1812–1817CrossRefPubMedGoogle Scholar
  19. 19.
    Zubkov AY, Mandrekar JN, Claassen DO, Manno EM, Wijdicks EF, Rabinstein AA (2008) Predictors of outcome in warfarin-related intracerebral hemorrhage. Arch Neurol 65:1320–1325CrossRefPubMedGoogle Scholar
  20. 20.
    Hankey GJ (2014) Intracranial hemorrhage and novel anticoagulants for atrial fibrillation: what have we learned? Curr Cardiol Rep 16:480CrossRefPubMedGoogle Scholar
  21. 21.
    Dolgin E (2013) Antidotes edge closer to reversing effects of new blood thinners. Nat Med 19:251CrossRefPubMedGoogle Scholar
  22. 22.
    Ebright J, Mousa SA (2014) Oral anticoagulants and status of antidotes for the reversal of bleeding risk. Clin Appl Thromb Hemost 21:105–114CrossRefPubMedGoogle Scholar
  23. 23.
    Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, Luan P, Hutchaleelaha A, Inagaki M, Conley PB, Phillips DR, Sinha U (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 19:446–451CrossRefPubMedGoogle Scholar
  24. 24.
    Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, Nar H, Litzenburger T (2013) A specific antidote for dabigatran: functional and structural characterization. Blood 121:3554–3562CrossRefPubMedGoogle Scholar
  25. 25.
    Enriquez A, Lip GY, Baranchuk A (2015) Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace. doi: 10.1093/europace/euv030 Google Scholar
  26. 26.
    Pollack CV Jr, Reilly PA, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, Dubiel R, Huisman MV, Hylek EM, Kamphuisen PW, Kreuzer J, Levy JH, Sellke FW, Stangier J, Steiner T, Wang B, Kam CW, Weitz JI (2015) Idarucizumab for dabigatran reversal. N Engl J Med 373(6):511–520CrossRefPubMedGoogle Scholar
  27. 27.
    Crowther M, Kitt M, McClure M, Sinha U, Lu G, Karbarz MJ (2013) Randomized, double-blind, placebo-controlled single ascending dose pharmacokinetic and pharmacodynamic study of PRT064445, a universal antidote for factor Xa inhibitors. Arterioscler Thromb Vas Biol 33:A10Google Scholar
  28. 28.
    Crowther M, Vandana M, Kitt M, Genmin L, Conley PB, Hollenbach SJ, Castillo J, Hutchaleelaha A, Karbarz MJ, Lin J, Barron L, Russell S, Levy G, Connolly S, Curnutte JT (2013) A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial Demonstrating Reversal Of Rivaroxaban-Induced Anticoagulation In Healthy Subjects By Andexanet Alfa (PRT064445), An Antidote For Fxa Inhibitors. Blood 122:3636Google Scholar
  29. 29.
    Crowther M, Kitt M, Lorenz T, Mathur V, Lu G, Hutchaleelaha A (2013) A phase 2 randomized, double-blind, placebo controlled trial of PRT4445, a novel, uniersal antidote for direct and indirect Factor Xa inhibitors. J Thromb Haemost 11(AS20):21Google Scholar
  30. 30.
    Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, Dishy V, Noveck RJ, Costin JC (2014) Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med 371:2141–2142CrossRefPubMedGoogle Scholar
  31. 31.
    Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF (1996) Lifetime cost of stroke in the United States. Stroke; a journal of cerebral circulation. 27:1459–1466CrossRefPubMedGoogle Scholar
  32. 32.
    Roger VL, Go AS, Lloyd-Jones DM, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, Moy CS, Mozaffarian D, Mussolino ME, Nichol G, Paynter NP, Soliman EZ, Sorlie PD, Sotoodehnia N, Turan TN, Virani SS, Wong ND, Woo D, Turner MB (2012) Heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation 125:e2–e220PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Ferreira J, Mirco A (2015) Systematic review of cost-effectiveness analyses of novel oral anticoagulants for stroke prevention in atrial fibrillation. Rev Port Cardiol 34:179–191PubMedGoogle Scholar
  34. 34.
    Coyle D, Coyle K, Cameron C, Lee K, Kelly S, Steiner S, Wells GA (2013) Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Value Health. 16:498–506CrossRefPubMedGoogle Scholar
  35. 35.
    Deitelzweig S, Amin A, Jing Y, Makenbaeva D, Wiederkehr D, Lin J, Graham J (2012) Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. J Med Econ. 15:776–785CrossRefPubMedGoogle Scholar
  36. 36.
    Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC (2013) Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 44:1676–1681CrossRefPubMedGoogle Scholar
  37. 37.
    Janzic A, Kos M (2014) Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control. Pharmacoeconomics. 33:395–408CrossRefGoogle Scholar
  38. 38.
    Eckman MH (2001) Patient-centered decision making: a view of the past and a look toward the future. Med Decis Making 21:241–247CrossRefPubMedGoogle Scholar
  39. 39.
    You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GY (2012) Antithrombotic therapy for atrial fibrillation: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e531S–e575SPubMedCentralCrossRefPubMedGoogle Scholar
  40. 40.
    McNeil BJ, Pauker SG, Sox J (1982) H.C., Tversky A. On the elicitation of preferences for alternative therapies. N Engl J Med 306:1259–1262CrossRefPubMedGoogle Scholar
  41. 41.
    Atrial Fibrillation Investigators (1994) Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 154:1449–1457CrossRefGoogle Scholar
  42. 42.
    Landefeld CS, Goldman L (1989) Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 87:144–152CrossRefPubMedGoogle Scholar
  43. 43.
    Eckman MH, Wise RE, Speer B, Sullivan M, Walker N, Lip GY, Kissela B, Flaherty ML, Kleindorfer D, Khan F, Kues J, Baker P, Ireton R, Hoskins D, Harnett BM, Aguilar C, Leonard A, Prakash R, Arduser L, Costea A (2014) Integrating real-time clinical information to provide estimates of net clinical benefit of antithrombotic therapy for patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 7:680–686CrossRefPubMedGoogle Scholar
  44. 44.
    Eckman MH, Wise RE, Naylor K, Arduser L, Lip GYH, Kissela B, Flaherty M, Kleindorfer D, Khan F, Schauer DP, Kues J, Costeai A (2015) Developing an Atrial Fibrillation Guideline Support Tool (AFGuST) for Shared Decision Making. Curr Med Res Opin 31:603–614CrossRefPubMedGoogle Scholar
  45. 45.
    Eckman MH, Singer DE, Rosand J, Greenberg SM (2011) Moving the Tipping Point: The Decision to Anticoagulate Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes 4:14–21PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Division of General Internal Medicine, Center for Clinical Effectiveness, University of Cincinnati Medical CenterUniversity of CincinnatiCincinnatiUSA

Personalised recommendations